Arena: Market Conditions Before Veeva
Pharmaceutical sales organizations · 2007 · United States
Specialist requirementsRegulatory constraintsEntrenched systems
A drug maker's sales reps called on physicians all day, far from a reliable connection, and FDA rules limited what a rep could say or do with them VE9. Every drug sample a rep handed over had to be tracked under federal rules, and any system holding regulated records had to be validated to work exactly as documented, which took significant time, expense and risk VE1. The CRM on offer was general-purpose software built for every industry, with life-sciences features added on top VVX-3. Companies ran it on their own servers, customized it heavily, and kept versions ten to fifteen years old because each upgrade was a project of its own VVX-2 VE1. Cloud CRM vendors lacked the industry functions and the validation, so drug makers used them only for basic tasks VE1.
How each step happened
Step 1 of 4 · 2007–13
A CRM built only for pharma, run as one validated cloud release for every customer
Veeva's innovation was one pharma CRM, validated and run in one place for every customer. "Before us, there was no validated application hosted in one place, accessible and freely shared among multiple customers," co-founder Matt Wallach says VE9. Because all customers ran the same version, new functions and regulatory changes reached everyone at once, several times a year VE1. Peter Gassner, the other co-founder, contrasts four-month release cycles with the four-year upgrades of the software drug makers ran VVX-4. That was the gap against Oracle: each Siebel customer paid for its own customized install and its validation, and each upgrade repeated the work VE1.
The founders brought both halves. Wallach had run Siebel's pharmaceutical and biotechnology division from 1998 to 2003 VE1. He says software built for a retailer or an insurer could not simply be handed to a pharma sales team, because FDA rules limit what reps may say to physicians and reps work far from a connection VE9. Gassner had built general-purpose software at IBM and PeopleSoft and had helped extend the Salesforce platform VE1 VE8.
The first product, launched in July 2007, handled physician profiles and drug samples, and by 2009 ran on handhelds VE8 VE7. It ran on Force.com, Salesforce's platform, so Veeva's engineers worked on pharma features, and Salesforce agreed not to back competing pharma sales software VE14 VE1. In 2011 came iRep, an offline iPad application used by more than 75% of CRM customers by 2013 VE1. This shared, validated release is what Veeva took to the largest drug makers.
Rivals Oracle added life-sciences features, such as sample management during calls, to its general Siebel 8 release in March 2007, with a choice of deployment options for each customer VVX-3. In 2015 a UBS analyst still described drug makers' CRM as highly customized on-premises systems, some 10 to 15 years old VVX-2. Cegedim sold a pharma-specific CRM on the same model VE1.
Novel ArchitectureVertical SpecializationFounder Domain Expertise
Step 2 of 4 · 2008–15
Win the largest drug makers directly; sell adoption services at full price
Selling began with the first release, so this step overlaps the first. Gassner's plan was to spend little, ship quickly and "sell it for a good price to as big a customer you can" VE6. He looked for drug makers unhappy with their systems VVX-4. Wallach recalls that these buyers also distrusted shared cloud software, so Veeva had to show it could replace the old system without disruption VE9. Novartis chose Veeva CRM for global use in October 2010, when three of the five largest drug makers had selected it VE19 VE11. By August 2013 customers included 33 of the 50 largest pharmaceutical companies VE1.
Veeva never gave away professional services, the configuration, implementation and training each customer needed. "If our people are not worth the customer paying for them, then they're not actually worth anything," Gassner says, even if a deal failed as a result VE6. He priced the software as a premium product too VE6. Services were 43% of revenue in the year to January 2013, and by 2015 more than 300 staff carried best practices from one customer to the next VE1 VE9 VE13.
Customers usually licensed a limited set of users first and added more later VE1. Subscription revenue retention, this year's subscription revenue from last year's customers against what they paid a year earlier, ran from 159% to 192% in fiscal 2011 to 2013 VE1. Customers, not investors, funded the company, which used about $3 million of outside money VE6 VE8. Gassner kept slightly fewer salespeople than demand allowed, so no rep would press a customer paying $20 million a year to meet a quota VE6. By 2015 UBS put Veeva at about 45% of life-sciences CRM VVX-2.
Rivals In 2013 trade press still called Oracle's Siebel the global leader in life-sciences CRM, with Cegedim of similar size, while IDC named Veeva the US leader VVX-1 VE22. By 2015 analysts said Veeva was taking share from both, whose technology they called older, and Beagle Research named Oracle Veeva's main competition VVX-2 VVX-9.
Lighthouse CustomersProfessional ServicesPremium PricingLand and Expand
Step 3 of 4 · 2010–17
Own platform for regulated content and customer data, sold to the same buyers
In 2010 the management team decided to become a multi-product company, a choice Gassner says means "you either crash the car or you make it big" VE6. Neither open-source content tools nor Salesforce fit the technology or the business model, so Veeva built its own platform VE16. Vault launched in 2011 for promotional materials and in September 2012 added regulatory submissions, clinical trials and quality documents VE1. As with CRM, a third-party firm validated each version against FDA and EU electronic-records rules, so customers could skip two qualification steps VE1.
The buyers were the drug makers step 2 had won. Network, a master file of physician and organization records in which one customer's update improved the data for all, followed in 2013 on another Veeva platform VE1 VE12. OpenData followed in 2015 with a standard licence customers could share, unlike older data vendors' closed contracts VE9. By 2017 content was about 35% of revenue VE6. These validated, connected records are what make the suite hard to leave.
Rivals Oracle's life-sciences expansion went to clinical software: it bought Phase Forward for about $685 million in 2010 and placed it in a separate Health Sciences unit, not beside Siebel CRM VVX-5. In content, Vault faced EMC, OpenText and Microsoft, whose general platforms service firms implemented VE1.
Multi-ProductPlatformization
Step 4 of 4 · 2013–26
Switching costs
The products from step 3 hold a drug maker's regulated records. Vault keeps an audit trail from the moment a document enters the system until it is archived, across marketing, medical, quality, clinical and regulatory work, and extends it to partners such as contract research organizations VE9. By 2016 CRM, Vault and Network were sold as one suite that Veeva connects itself VE13. Leaving means moving documents with their approval history and validating the replacement, a significant expense by the prospectus's account, while regulated work continues VE1. By 2024 commercial customers owned about four Veeva products on average, and by 2025 Veeva held about 80% of life-sciences CRM VVX-7 VVX-6.
CRM shows the limit
The hold is weakest where Veeva did not own the platform. In December 2022 it said CRM would move from Salesforce's platform to its own Vault platform, asking every CRM customer to migrate by 2030 VE20. The Salesforce agreement ended on September 1, 2025, and four weeks later Salesforce launched a life-sciences CRM with Pfizer as an early adopter VE12 VE4. By January 2026 more than 125 customers were live on Vault CRM and 10 of the top 20 biopharmas had committed to it VE5. The move puts CRM beside the records from step 3; Gassner says it simplifies customers' systems VE20.
Rivals By 2025 trade press named Salesforce and Veeva the dominant pharma CRMs and put Oracle among the others VVX-6. Cegedim sold its CRM to IMS Health in 2014, and IQVIA's Salesforce-based CRM of 2017 did not dent Veeva's share VVX-8 VVX-7. Salesforce, with Pfizer, is the test of CRM's hold VE4.
Switching costs